NCT00444535 - Lapatinib and Bevacizumab for Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2007

Primary Completion Date

July 22, 2008

Study Completion Date

June 19, 2020

Conditions

Neoplasms, Breast

Interventions

DRUG

lapatinib

1500 mg oral lapatinib (once daily)

DRUG

bevacizumab

10 mg/kg intravenous bevacizumab (every two weeks)

Trial Locations (9)

Novartis Investigative Site, New York

Novartis Investigative Site, Sleepy Hollow

Novartis Investigative Site, Rockville Centre

Novartis Investigative Site, Commack

Novartis Investigative Site, Hollywood

Novartis Investigative Site, Tampa

Novartis Investigative Site, Tucson

Novartis Investigative Site, San Francisco

Novartis Investigative Site, Basking Ridge